Lymphoma, Non-Hodgkin D008228

Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Lymphoma » Lymphoma, Non-Hodgkin

Diseases [C] » Hemic and Lymphatic Diseases [C15] » Lymphatic Diseases » Lymphoproliferative Disorders » Lymphoma » Lymphoma, Non-Hodgkin

Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders » Lymphoproliferative Disorders » Lymphoma » Lymphoma, Non-Hodgkin

Description

Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.   MeSH

Subtype Terms (5)

Lymphoma, B-Cell
270 drugs (102 approved, 168 experimental)

Lymphoma, Follicular
312 drugs (131 approved, 181 experimental)

Lymphoma, Large-Cell, Immunoblastic
262 drugs (133 approved, 129 experimental)

Lymphoma, Mantle-Cell
297 drugs (124 approved, 173 experimental)

Lymphoma, T-Cell
216 drugs (101 approved, 115 experimental)


Phase 3 Indicated Drugs (78)

Phase 2 Indicated Drugs (261)

111in zevalin

125-iodine

68ganota-anti-mmr-vhh2

90y-epratuzumab tetraxetan

9-ing-41

abt-510

acalabrutinib (calquence)

acetylcysteine (mucomyst)

agatolimod

alemtuzumab (campath)

alisertib

allogeneic adipose derived mesenchymal stem cell

allogeneic bone marrow derived mesenchymal stem cell

allogeneic cd19 car-t cells

allogeneic cd20 car-t cell

allogeneic natural killer cells

allogeneic transplant donor lymphocytes, depleted of tcr-αβ t cells and b cells; enriched for nk cells and tcrγδ t cells

alt-803

alvocidib

alx148

amifostine (ethyol)

anakinra (kineret)

angiotensin 1-7

anti-b1 antibody

antineoplaston a10

arag

atezolizumab (tecentriq)

atorvastatin (lipitor)

autologous-allogeneic tandem hematopoietic stem cell

autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing t lymphocytes

autologous cd19/cd22 chimeric antigen receptor t-cells

autologous effector lymphocytes expanded ex-vivo

autologous hematopoietic cell

autologous hematopoietic stem cells

autologous immunoglobulin idiotype-klh conjugate vaccine

autologous lymphocytes

autologous mesenchymal stem cells

autologous platelets

autologous regulatory t cells

avelumab (bavencio)

axicabtagene ciloleucel (Yescarta)

axitinib (inlyta)

azacitidine (vidaza)

basiliximab (simulect)

beclomethasone (vanceril)

belinostat (beleodaq)

beractant (survanta)

bevacizumab (avastin)

bgb-3111

bi-1206

bkt-140

blinatumomab (blincyto)

bone marrow cells

bosutinib (bosulif)

burixafor

busulfan (myleran)

bvd-523

capivasertib

car-t targeted cd19/cd20/cd22/cd30

cd19 car-t cells

cd20 car-t cells

cd3+ teff cells

cd45-depleted allogenic peripheral blood stem cell

cdx-301

cerdulatinib

cetuximab (erbitux)

Phase 1 Indicated Drugs (270)


Organization Involved with Phase 3 Indications (123)

Organization Involved with Phase 2 Indications (330)

Aalborg University

Aarhus University

Abbott

Academic and Community Cancer Research United

Acibadem University

AIDS Malignancy Consortium

Albany Medical College

Alberta Cancer Foundation

Alopexx

Altor Bioscience

American Cancer Society, Inc.

American Society of Clinical Oncology

AnorMED

Aprea Therapeutics AB

Arbeitsgemeinschaft medikamentoese Tumortherapie

Artiva Biotherapeutics, Inc.

Asana BioSciences

Ascenta Therapeutics

Astellas

AstraZeneca

Autolus Limited

Auxilio

Azienda Ospedaliera San Giovanni Battista

AZ Sint-Jan

Badalona Hospital Germans Trias i Pujol

Bambino Gesù Hospital and Research Institute

Basque Country University

Baxalta

Baylor University

Beijing Immunochina Medical Science & Technology Co., Ltd.

Bellicum Pharmaceuticals

BioInvent International AB

BioLineRx, Ltd.

Biothera

Boryung Pharmaceutical Company

Brown University

Burzynski Research Institute

CARsgen Therapeutics, Ltd.

Case Western Reserve University

Celldex Therapeutics

Cellgenix

Centaurus Biopharma Co., Ltd.

Central South University

Centre Henri Becquerel

Centro di Riferimento Oncologico - Aviano

Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Centro Medico Nacional La Raza, IMSS

Chang Gung University

Children's Cancer Group, China

Children's Hospital Los Angeles

Chimei Medical Center

Chipscreen Biosciences, Ltd.

Chonbuk National University

Chu De Liège

CHU Mont-Godinne

Clinica Universidad de Navarra

Consortium for Improving Survival of Lymphoma

Constant Pharmaceuticals

Cornell University

CRISPR Therapeutics

CureTech Ltd

Cytokinetics

Damon Runyon Cancer Research Foundation

Doris Duke Charitable Foundation

Duke University

Dynavax Technologies Corporation

Eisai

Emergent BioSolutions

Emory University

Facet Biotech

Fondazione Italiana Diabete Onlus

Forty Seven, Inc.

Franklin Square Hospital Center

French Innovative Leukemia Organisation

French National Agency for Research on AIDS and Viral Hepatitis

Fudan University

Fundación Leucemia y Linfoma, Spain

Gabrail Cancer Center

Gemeinschaftspraxis Porowski & Koniczek, Heilbronn, Germany

Genmab

Genor BioPharma Co., Ltd.

Genta

Georgetown University

Geriatric Oncology Consortium

German Society of Cancer e.V.

Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH

Ghent University

GLyPharma Therapeutic

GMP BIO Co., LTD.

Government of Taiwan

Gracell Biotechnology Ltd.

Green Cross Corporation

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Gruppo Italiano Malattie EMatologiche dell'Adulto

Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie

GWT-TUD GmbH

Harvard University

Henan Medical University

Henan University of Traditional Chinese Medicine

Hopital A Beclere Clamart

Hôpital Maisonneuve Rosemont, Montréal, QC, Canada

Hospital Auxilio Mutuo

Hospital Carlos Haya

Hospital de Galdakao

Hospital de Getafe

Hospital de Jerez

Hospital de Segovia

Hospital Fundación de Alcorcon

Hospital Jerez de la Frontera

Hospital Morales Meseguer

Hospital Severo Ochoa

Hospital Son Espases

Hospital Txagorritxu

Hospital Universitario Arnau de Vilanova de Lleida

Hospital Universitario Central de Asturias

Hospital Universitario Puerta del Mar

Hospital Virgen de la Concha

Huazhong University of Science and Technology

Human Genome Sciences

Humboldt University

Icahn School of Medicine at Mount Sinai

ICON

Immune Design

ImmunogenX

Indiana University

Inex Pharmaceuticals

Innovative Therapies For Children with Cancer Consortium

Institut Paoli-Calmettes

InterMune

International Extranodal Lymphoma Study Group

Jazz Pharmaceuticals

Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd

Jichi Medical University

Johannes Gutenburg University

Johns Hopkins University

JSS Medical Research Inc.

Juno Therapeutics, Inc.

Juventas Therapeutics, Inc.

Kantonsspital Aarau

Kaohsiung Medical University

Katholieke Universiteit Leuven

Keimyung University

Keio University

Kite Pharma, Inc.

Korea Cancer Center Hospital

Kyowa Hakko Kirin

Leadiant Biosciences, Inc.

Lederle

LifeBridge Health

Ligand Pharmaceuticals

Lund University

Lymphoma Disease Committee of TCOG

Lymphoma Research Foundation

Mackay Medical College

Marche Polytechnic University

McGill University

Medical University of Vienna

MedImmune

Memgen, LLC

Memorial Sloan-Kettering Cancer Center

Methodist Cancer Center, Houston, Texas

MethylGene Inc.

Miltenyi Biotec, Inc.

Mirati Therapeutics Inc.

Molecular Templates

MorphoSys

NantCell, Inc.

National Cancer Center, Korea

National Cheng Kung University

National Institute on Aging (NIA)

National Taiwan University

National University of Singapore

New Mexico Cancer Care Alliance

Nordic Nanovector

North Central Cancer Treatment Group

Northern Italy Leukemia Group

Northwestern University

Norwood Immunology Limited

Novacea

Ohio State University

Oncoceutics, Inc.

Oncology Specialists, S.C.

Onxeo

Oregon Health and Science University

Osaka University

Ospedale Centrale di Bolzano

Ospedale S. Giovanni Bellinzona

Otsuka

Ozmosis Research Inc.

PDL BioPharma

PharmaMar

Pharmatech

Plexxikon

Polaris Group

Polyphor Ltd.

Portola Pharmaceuticals

Precision BioSciences, Inc.

PrECOG, LLC.

Prologue Research International

Pusan National University

Regeneron

Regional Hospital of Bolzano

Rhizen Pharmaceuticals SA

Rhode Island Hospital

Royal Marsden Hospital NHS Trust

Rutgers University

SCRI Development Innovations

Seattle Genetics

Shanghai Bioray Laboratory Inc.

Shanghai Ming Ju Biotechnology Co., Ltd.

Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Shanghai YingLi Pharmaceutical Co. Ltd.

Shijiazhuang Pharma Group (CSPC)

Sichuan University

Sierra Oncology, Inc.

Sinocelltech Ltd.

Sirna Therapeutics

Soochow University

Soonchunhyang University

Spanish National Health System

Spectrum Pharmaceuticals

St. John Hospital and Medical Center, Van Elslander Cancer Center

Stony Brook University

Sungkyunkwan University

Sun Yat-Sen University

SymBio Pharmaceuticals

Systemix

TaiGen Biotechnology Co., Ltd.

Takara Bio Inc.

Takeda

Targazyme, Inc.

TCR2 Therapeutics

Technical University of Munich

Technion University

Temple University

The Alvin and Lois Lapidus Cancer Institute

The EMMES Corporation

The First People's Hospital of Changzhou

The Leukemia and Lymphoma Society

The Lymphoma Academic Research Organisation

Theradex

The Scientific and Technological Research Council of Turkey

The University of Texas, Dallas

The Wayne D. Kuni and Joan E. Kuni Foundation

Thomas Jefferson University

Tibotec

Timmune Biotech Inc.

Translational Research Institute for Metabolism and Diabetes, Florida

Tularik

Tzu Chi University

Universidad Autonoma de Barcelona

Universidad Autonoma de Madrid

Universidad Autonoma de Nuevo Leon

Universidad Complutense de Madrid

Universidad de Murcia

Universitair Ziekenhuis Gent

University Alicante

University of Alabama, Birmingham

University of Antwerp

University of Arizona

University of Barcelona

University of Brescia

University of Calgary

University of California, Davis

University of California, San Diego

University of Chicago

University of Colorado, Denver

University of Copenhagen

University of Florida

University of Freiburg

University of Hamburg

University of Heidelberg

University of Illinois at Chicago

University of Kentucky

University of Las Palmas de Gran Canaria

University of Leeds

University of Liege

University of Limoges

University of Magdeburg

University of Mannheim

University of Maryland

University of Massachusetts

University of Medicine and Dentistry of New Jersey

University of Miami

University of Michigan

University of Milan

University of Minnesota

University of Montpellier

University of Montreal

University of New Mexico

University of Paris

University of Pittsburgh

University of Poitiers

University of Roma La Sapienza

University of Salamanca

University of Santiago

University of Sherbrooke

University of Southern California

University of Southern Denmark

University of South Florida

University of Strasbourg

University of Tuebingen

University of Turin

University of Ulm

University of Ulsan

University of Utah

University of Valencia

University of Vermont

University of Vienna

University of Virginia

University of Witten/Herdecke

University of Zagreb

University of Zaragoza

US Oncology

Vanderbilt University

Vical

Virginia Commonwealth University

Vita-Salute University of Milano. Italy

Wake Forest University

Washington University in St. Louis

Wayne State University

West Virginia University

Wyeth

Xcyte Therapies

Xuzhou Medical University

Xynomic Pharmaceuticals, Inc.

Yeshiva University

Yonsei University

Zhejiang DTRM Biopharma

ZNA Antwerpen

Organization Involved with Phase 1 Indications (112)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.